Background {#Sec1}
==========

In patients with reduced life expectancy, such as after a diagnosis of metastatic cancer, there may be a substantial increase in pharmacotherapeutic burden \[[@CR1]\]. Approaching end-of-life, there can often be a treatment paradigm shift to that of palliative care. Accordingly, medications prescribed to patients with advanced cancer may be reviewed regularly and those unlikely to provide benefit, or those associated with increased risk of side-effects, can be discontinued \[[@CR1]\]. Statins, or 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, are used in the primary prevention of cardiovascular disease, with treatment benefits accruing over at least 2 years \[[@CR2]\]. In patients with established cardiovascular disease, statins may be used as secondary prevention through long-term lipid lowering, and short-term anti-inflammatory effects \[[@CR3]\]. Therefore, the potential benefit of statin use in those with reduced life expectancy may be limited to high-risk patients \[[@CR4]\], and should be considered for discontinuation in those who are unlikely to benefit.

Several studies have investigated statin use in those with reduced life expectancy, which suggest that many patients will cease statin treatment by the time of death \[[@CR5]--[@CR9]\]. However, these are largely cross-sectional studies reporting statin exposure at the time of death. Observational studies investigating the association between statin exposure and cancer outcomes, not accounting for changes in statin utilization towards the end-of-life, are likely to be associated with reverse causation bias. This occurs when changes in prognosis or disease status lead to a change in the exposure of interest. There is little empirical evidence informing the choice of an appropriate exposure lag time for adjusting for reverse causation bias, as investigators do not always have *a priori* assumptions based on biological evidence \[[@CR10]\]. There is little data to describe the changes in statin exposure longitudinally prior to death, which is vital for determining an appropriate exposure lag period.

Two of the most prevalent invasive cancers are breast and colorectal cancer \[[@CR12]\]. Therefore, the aim of this study was to describe the changes in statin exposure longitudinally prior to death in patients in Ireland with breast or colorectal cancer which are, in particular, to (i) estimate the probability of initiating statin therapy in the 5 years prior to a death from cancer, (ii) estimate the probability of continuing statin-use towards end-of-life, and (iii) compare these longitudinal statin exposures with statin exposures measured in matched cancer-survivors over the same time period, thus establishing an appropriate statin exposure lag time.

Methods {#Sec2}
=======

Setting and data Sources {#Sec3}
------------------------

This study was carried out using individual-level patient records from the National Cancer Registry Ireland (NCRI), which are linked to prescription dispensing records from Ireland's Health Services Executive (HSE) Primary Care Reimbursement Services (PCRS) pharmacy claims database. These linked datasets have been described previously \[[@CR13]\]. Briefly, the NCRI records details about all cancers diagnosed in the population normally resident in Ireland. For each tumor diagnosed, hospital-based tumor registration officers (TRO) collect information on patient and tumor characteristics, and treatment received. Information on mortality, date, and cause of death are obtained from linked death certificates. The completeness of NCRI data has been evaluated and is estimated to be at least 95% for breast cancer, and 96% for colorectal cancer \[[@CR14]\]. The use of anonymized data held by the NCRI is covered by the Health (Provision of Information) Act 1997.

The PCRS is responsible for financial reimbursement of dispensed medication claims made under the General Medical Services (GMS) community drug scheme. The GMS scheme provides subsidized healthcare, including prescription medications at no or minimal cost, to approximately one third of the Irish population, with eligibility assessed by a combination of means test and age (≥70 years). The PCRS pharmacy claims database records all drugs dispensed under the GMS scheme; this includes all statin prescriptions which are not available over-the-counter in Ireland. Drugs are coded according to WHO-ATC classification system \[[@CR15]\].

Cohort and exposure definitions {#Sec4}
-------------------------------

The study population was defined as all patients diagnosed with stages I--III, invasive breast (ICD-10 C50) or colorectal cancer (ICD-10 C18-C20), between 1 January 2001 and 31 December 2009, with continuous eligibility for the GMS scheme starting at least 1 year prior to diagnosis. Patients with prior invasive cancers (other than non-melanoma skin cancer) were excluded, as were men with a diagnosis of breast cancer.

From this defined study population, we identified patients who died of their cancer (cases) between 1 January 2001 and 31 December 2009, using SEER definitions for breast and colorectal cancer-specific death \[[@CR16]\]. Patients who were alive on 31 December 2011 were identified as cancer survivors, and were used as controls. Using a greedy matching algorithm \[[@CR17]\], controls were matched to cases separately for breast (2:1) and colorectal cancer (1:1), by tumor stages (I, II, III), age at diagnosis (5 year caliper), gender (colorectal cancer only), and pre-diagnostic statin use (yes/no). Where cases have pre-diagnostic statin exposure, we also matched controls on the intensity of statin exposure in the year prior to diagnosis (10% caliper). The date of death for each case was used as an index date for matched controls and a reference point to calculate statin exposure.

All prescriptions for statins were identified using the PCRS database; drugs are coded using WHO-ATC drug classifications \[[@CR15]\](Online Resource [1](#MOESM1){ref-type="media"}). We used the dose and number of days' supply on each statin prescription to establish longitudinal exposure histories for each patient by assigning the days' supply from each prescription (normally of 1 month duration) to sequential days from the date of dispensing \[[@CR18]\].

For cases and matched controls, we used these statin exposure histories to calculate measures of statin use in sequential pre-defined exposure windows starting at date of death for cases, or index date for controls, and continuing up to diagnosis, or for a maximum of 5 years (whichever comes first). We chose a duration of maximum 5 years prior to death as the median survival post breast or colorectal cancer recurrence which is 2--2.5 years \[[@CR19], [@CR20]\]. First, we identified patients without statin exposure prior to diagnosis who initiated statin treatment in the time post-diagnosis within each exposure window. Second, for those patients with statin exposure prior to diagnosis, we identified patients with a supply of statins during each exposure window. From these pre-mortality measures of statin exposure, we estimated, for each exposure window, (i) the probability of starting statin use as death approached, and (ii) the probability of continuing statin use towards end-of-life.

Statistical analyses {#Sec5}
--------------------

The frequency of cases and controls were tabulated by clinical and socio-demographic characteristics. Descriptive statistics were weighted by the inverse number of controls matched to each case, and standardized differences were used to assess balance (d \< 0.1) in the matched covariates \[[@CR17]\]. The probability of (i) statin initiation and (ii) maintaining statin use in each exposure window were plotted for cases and matched controls with respect to the length of time prior to death/index date. Smoothing splines were fitted with locally weighted error sum of squares of regression \[[@CR21]\].

Conditional binomial models were used to estimate relative risks (RR) and risk differences (RD) with 95% confidence intervals (CI) for (i) initiating statin treatment and (ii) continuing statin use in cases versus controls. These analyses were carried out for statin exposure immediately prior to death/index date, and repeated for consecutive preceding windows. All analyses were performed with SAS®, version 9.3 (SAS® Institute Inc., Cary, NC). Results were considered statistically significant at a two-sided α-level of 0.05.

Results {#Sec6}
=======

Study population {#Sec7}
----------------

The selection of breast (*N* = 8711) or colorectal cancer (*N* = 8520) patients from the NCRI database is shown in a flow diagram (Fig. [1](#Fig1){ref-type="fig"}), and the patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. The median age at diagnosis of patients with breast or colorectal cancer was 69 and 75 years respectively, and 28.8% of breast and 11.5% of colorectal cancer patients were taking statins in the year prior to cancer diagnosis. From these breast and colorectal cancer cohorts, we matched 1055 breast or 1688 colorectal cancer cases (deaths) to 1557 and 1668 cancer controls (survivors), respectively.Fig. 1Study flow diagram Table 1Characteristics of matched cases and controls---breast cancer and colorectal cancerCharacteristicBreast cancerColorectal cancerAll *N* = 8711Breast cancer death *N* = 1055Matched control^a,\ b,\ c^ *N* = 1577All *N* = 8520Colorectal cancer death *N* = 1668Matched control^a,\ b^ *N* = 1668Matched covariates Age in years--Median (IQR)^d^69(57.77)71(58.78)70(59.77)75 (70.80)75 (69.79)74 (68.78) Tumor stage--*N* (%)^e^I2651 (30.4)141 (13.3)244 (13.3)1546 (18.2)184 (11.0)184 (11.0)II4603 (52.9)623 (59.1)995 (59.1)3608 (42.3)756 (45.3)756 (45.3)III1457 (16.7)291 (27.6)338 (27.6)3366 (39.5)728 (43.7)728 (43.7) Pre-diagnostic statin use--*N* (%)^f^2508 (28.8)248 (23.5)377 (23.5)977 (11.5)198 (11.9)198 (11.9) Pre-diagnosis statin intensity--Mean (SD)^f^0.77 (0.3)0.77 (0.32)0.77 (0.26)0.73 (0.32)0.74 (0.32)0.75 (0.32) Gender Male--*N* (%)------4682 (54.9)915 (54.9)874 (52.4)Unmatched covariates Treatments - *N* (%)^g^Chemotherapy3260 (37.4)449 (42.6)772 (49.0)2697 (31.7)570 (34.1)745 (44.6)Radiation5355 (61.5)566 (53.7)1102 (69.9)1370 (16.1)370 (22.2)260 (15.6)Surgery7487 (86.0)803 (76.1)1480 (94.9)7971 (91.4)1362 (81.7)1628 (97.6)All three modalities2519 (29.0)324 (30.7)624 (39.6)885 (10.4)204 (12.2)211 (12.7) Tumor grade--*N* (%)^d^1862 (9.9)30 (2.8)141 (8.9)530 (6.2)80 (4.8)104 (6.2)24275 (49.1)369 (35.0)821 (52.1)6017 (70.6)1071 (64.2)1252 (45.1)32762 (31.7)509 (48.3)504 (32.0)1045 (12.3)270 (16.2)184 (11.0)Unspecified812 (9.3)147 (13.9)111 (7.0)900 (10.6)247 (14.8)128 (7.7) Smoking--*N* (%)^d^Current1747 (20.1)235 (22.3)298 (18.9)1165 (13.7)282 (16.9)200 (12.0)Past3993 (45.8)118 (11.2)199 (12.6)3415 (40.1)302 (18.1)347 (20.8)Never1004 (11.5)437 (41.4)783 (49.7)1731 (20.3)640 (38.4)749 (44.9)Unspecified1967 (22.6)265 (25.1)297 (18.8)2209 (25.9)444 (26.6)372 (22.3) Deprivation Score--*N* (%)^d^1 - Low1098 (12.6)133 (12.6)207 (13.1)1225 (14.4)211 (12.7)269 (16.1)2954 (11.0)113 (10.7)184 (11.6)926 (10.9)168 (10.1)192 (11.5)31091 (12.5)129 (12.2)196 (12.4)1157 (13.6)255 (15.3)202 (12.1)41563 (17.9)181 (17.1)297 (18.8)1550 (18.2)300 (18.0)288 (16.8)5 - High3428 (39.4)424 (40.2)602 (38.2)3163 (37.1)633 (38.0)617 (17.3)Unspecified577 (6.6)75 (7.1)91 (5.8)499 (5.9)101 (6.1)100 (6.0)*IQR* inter-quartile range, *SD* standard deviation^a^Breast cancer cases and controls matched in ratio of 1:2^b^Matched on tumor stages (I, II, III), age (5-year caliper) and pre-diagnostic statin use (yes/no). Pre-diagnostic statin users were also matched on the intensity of pre-diagnostic statin exposure (10% caliper)^c^Means and percentages for controls were weighted by the inverse number of controls matched to each case^d^At the time of cancer diagnosis^e^AJCC Cancer Staging Manual 6th Edition. Springer, 2002^f^In the year pre cancer diagnosis^g^Any chemotherapy, radiation, or surgery in the year post cancer diagnosis

Statin initiation approaching end of Life {#Sec8}
-----------------------------------------

The results from conditional bionomial model analyses investigating statin initiation in the 5 years prior to death/index date are shown in Online Resources [2](#MOESM1){ref-type="media"} and [3](#MOESM1){ref-type="media"}. Rates of statin initiation did not seem to differ as breast or colorectal cancer patients approached end of life. In the 6 months prior to death/index date, 1.4% of breast and 1.2% of colorectal cases initiated statin use, as compared to 2.1% and 1.4% of controls, respectively.

Continued statin use at end of Life {#Sec9}
-----------------------------------

In the 5 years prior to death or matched index date, we calculated the proportion of statin users who maintained statin use for both breast and colorectal cancer patients in consecutive time windows, and the results are shown in Tables [2](#Tab2){ref-type="table"} and Table [3](#Tab3){ref-type="table"}. This data is presented graphically for breast (Fig. [2](#Fig2){ref-type="fig"}) and colorectal cancer (Fig. [3](#Fig3){ref-type="fig"}). For both breast and colorectal cancer patients, the probability of continuing statin use was comparable in cases and controls up to approximately 1 year prior to death/index date. Subsequently, statin use declined for cancer cases when compared to matched cancer survivors. When compared to matched controls, the probability of continued statin use in breast cancer cases was significantly lower from 3 months prior to death (RR 0.86 95% CI 0.79, 0.94)(Table [2](#Tab2){ref-type="table"}). In colorectal cancer cases, when compared to matched controls, the probability of continued statin use was lower from 12 months prior to death (RR 0.90 95% CI 0.81, 1.00), and significantly lower at 3 months prior to death from colorectal cancer (RR 0.77 95% CI 0.68, 0.88)(Table [Table3](#Tab3){ref-type="table"}).Table 2Relative risks and risk differences for continued statin use in five years prior to breast cancer-specific deathStatin use within exposure windowsBreast cancer ^a,\ b^Cases-*N* (statin use %)Controls-*N* (statin use %)^c^RR (95%CI)RD (95%CI)49--60 months prior to death/index26 (88.5)31 (87.1)1.02(0.85, 1.21)0.01(−0.14, 0.17)43--48 months prior to death/index51 (90.2)65 (87.7)1.03(0.91, 1.16)0.03(−0.08, 0.13)37--42 months prior to death/index62 (90.3)82 (89.0)1.01(0.91, 1.13)0.01(−0.08, 0.11)33--36 months prior to death/index90 (87.8)123 (88.6)0.99(0.90, 1.09)−0.01(−0.09, 0.07)29--32 months prior to death/index110 (88.2)154 (90.3)0.98(0.91, 1.05)−0.02(−0.09, 0.05)25--28 months prior to death/index126 (89.7)175 (89.1)1.01(0.94, 1.08)0.01(−0.06, 0.07)22--24 months prior to death/index143 (88.1)202 (86.6)1.02(0.95, 1.09)0.01(−0.05, 0.08)19--21 months prior to death/index160 (87.5)229 (85.2)1.03(0.96, 1.1)0.02(−0.04, 0.08)16--18 months prior to death/index176 (84.7)258 (84.5)1.00(0.93, 1.08)0.00(−0.06, 0.06)13--15 months prior to death/index188 (84.0)278 (81.7)1.03(0.96, 1.1)0.02(−0.03, 0.08)10--12 months prior to death/index198 (83.8)294 (83.7)1.00(0.93, 1.08)0.00(−0.06, 0.06)7--9 months prior to death/index214 (81.3)321 (84.7)0.96(0.89, 1.03−0.03(−0.10, 0.03)4--6 months prior to death/index224 (79.9)338 (83.1)0.96(0.89, 1.04)−0.03(−0.09, 0.03)3 months prior to death/index234 (70.5)352 (81.8)*0.86*(*0.79*, *0.94*)\*−*0.11*(−*0.18*, −*0.05*)\*2 months prior to death/index238 (66.4)359 (82.2)*0.81*(*0.73*, *0.89*)\*−*0.16*(−*0.23*, −*0.09*)\*4--3 weeks prior to death/index242 (56.6)365 (79.5)*0.71*(*0.63*, *0.80*)\*−*0.23*(−*0.30*, −*0.16*)\*2 weeks prior to death/index245 (50.2)371 (77.1)*0.65*(*0.57*, *0.74*)\*−*0.27*(−*0.34*, −*0.2*)\*1 week prior to death/index247 (45.7)375 (76.5)*0.60*(*0.52*, *0.69*)\*−*0.30*(−*0.38*, −*0.23*)\*\**P* \< 0.05^a^Breast cancer cases and cancer-controls matched in ratio of 1:2^b^Matched on tumor stages (I, II, III), age (5-year caliper) and pre-diagnostic statin use (yes/no). Pre-diagnostic statin users were also matched on the intensity of pre-diagnostic statin exposure (10% caliper). Colorectal cancer patients are also matched on gender (male, female)^c^Percentages for controls were weighted by the inverse number of controls matched to each case Table 3Relative risks and risk differences for continued statin use in 5 years prior to colorectal cancer-specific deathStatin use within exposure windowsColorectal cancer^a,\ b^Cases-N (statin use %)Controls-N (statin use %)^c^RR (95%CI)RD (95%CI)49--60 months prior to death/index17 (94.1)17 (76.5)1.23(0.97, 1.56)0.18(0.00, 0.36)43--48 months prior to death/index31 (83.9)31 (83.9)1.00(0.83, 1.20)0.00(−0.15, 0.15)37--42 months prior to death/index42 (88.1)42 (88.1)1.00(0.88, 1.14)0.00(−0.11, 0.11)33--36 months prior to death/index55 (87.3)55 (85.5)1.02(0.90, 1.16)0.02(−0.09, 0.13)29--32 months prior to death/index64 (90.6)64 (85.9)1.05(0.95, 1.17)0.05(−0.04, 0.14)25--28 months prior to death/index72 (86.1)72 (86.1)1.00(0.89, 1.13)0.00(−0.10, 0.10)22--24 months prior to death/index87 (82.8)87 (82.8)1.00(0.90, 1.12)0.00(−0.09, 0.09)19--21 months prior to death/index100 (84.0)100 (82.0)1.02(0.93, 1.13)0.02(−0.06, 0.10)16--18 months prior to death/index106 (80.2)106 (84.0)0.96(0.86, 1.06)-0.04(−0.12, 0.04)13--15 months prior to death/index118 (80.5)118 (87.3)0.92(0.84, 1.02)-0.07(−0.15, 0.01)10--12 months prior to death/index128 (78.1)128 (86.7)0.90(0.81, 1.00)-0.09(−0.17, 0.00)7--9 months prior to death/index138 (76.1)138 (81.9)0.93(0.83, 1.04)-0.06(−0.15, 0.03)4--6 months prior to death/index148 (75.0)148 (83.8)0.90(0.80, 1.00)-0.09(−0.17, 0.00)3 months prior to death/index162 (61.1)162 (79.0)*0.77*(*0.68*, *0.88*)\*−*0.18*(−*0.27*, −0.09)\*2 months prior to death/index171 (56.1)171 (79.5)*0.71*(*0.61*, *0.81*)\*−*0.23*(−*0.32*, −*0.14*)\*4--3 weeks prior to death/index185 (42.7)185 (77.8)*0.55*(*0.46*, *0.66*)\*−*0.35*(−*0.44*, −*0.26*)\*2 weeks prior to death/index192 (34.9)192 (77.1)*0.45*(*0.37*, *0.55*)\*−*0.42*(−*0.51*, −*0.36*)\*1 week prior to death/index195 (30.8)195 (77.4)*0.40*(*0.32*, *0.49*)\*−*0.47*(−*0.55*, −*0.38*)\*\**P* \< 0.05^a^Colorectal cancer cases and cancer-controls matched in ratio of 1:1^b^Matched on tumor stages (I, II, III), age (5-year caliper) and pre-diagnostic statin use (yes/no). Pre-diagnostic statin users were also matched on the intensity of pre-diagnostic statin exposure (10% caliper). Colorectal cancer patients are also matched on gender (male, female)^c^Percentages for controls were weighted by the inverse number of controls matched to each case Fig. 2Probability of continued statin use prior to breast cancer specific death Fig. 3Probability of continued statin use prior to colorectal cancer specific death

In the week prior to death, the probability of continued statin use was 45.7% for breast cancer cases, compared to 76.5% of breast cancer controls (RR 0.60 95% CI 0.52, 0.69), and 30.8% for colorectal cancer cases versus 77.4% for cancer controls (HR 0.40 95% CI 0.32, 0.49).

Discussion {#Sec10}
==========

This study aimed to describe changes in statin exposure prior to death from breast or colorectal cancer; the probability of continuing statin use was found to be significantly lower in the 3 to 6 months prior to death from these cancers. This decline in statin use may be the result of a change in the health care priorities of the patient, and/or reduction in the pharmacotherapeutic burden \[[@CR22]\]. In contrast, the number of patients initiating statin use did not differ between those who died of their cancer and those who did not. This suggests that a life-limiting diagnosis does not affect the prescribing of preventative medications.

Several studies have investigated statin use in those with reduced life expectancy \[[@CR4], [@CR5], [@CR7], [@CR9], [@CR11]\]. In the time since these articles were published, a randomized study of statin discontinuation in the palliative care setting was carried out \[[@CR23]\]. This study showed that stopping statin therapy in patients with a limited life expectancy was safe for the patients, with no significant difference in the time to cardiac event, and may be associated with improved quality of life \[[@CR23]\]. Although there are currently no clinical guidelines on ceasing statin treatment, this clinical trial suggests that it is safe to do so in patients with limited life expectancy. In addition, Lindsay et al. have developed deprescribing guidelines (OncPal) for oncological palliative care in an Australian tertiary hospital setting, and they suggest statins as a potentially inappropriate medication that should be considered for discontinuation \[[@CR24]\]. Given the lack of clinical guidelines on statin therapy discontinuation in the Irish setting, these studies may prove useful in the clinical decision making process in regards to medication received by patients who are approaching death.

The decision to discontinue statin treatment approaching the end-of-life may be the result of a decision to reduce pharmacotherapeutic burden on the patient. However, there may also be other clinical reasons for deciding to cease statins. Cancer cachexia is associated with changes in body composition and loss of muscle mass resulting in worsening functional performance, reduced quality of life, and reduced prognosis \[[@CR25]\]. Cachexia affects approximately 50% of all cancer patients, and this figure increases to over 80% in the last 2 weeks of life \[[@CR26]\]. Preclinical studies showed that treatment of animal models with simvastatin caused a further decrease in muscle mass and suggested that statin treatment in cachectic patients should be used with caution \[[@CR27], [@CR28]\]. Malnutrition and cachexia in chemotherapy patients have been expressed as reasons for discontinuing lipid-modifying medications \[[@CR5]\]. In addition, statins are metabolised in the liver by the cytochrome P450 enzyme family, which are altered by chemotherapeutic agents used in colorectal cancer, such as capecitabine and irinotecan, which may result in altered drug metabolism \[[@CR29]\]. As well as reducing adverse physical effects on the cancer patient, prescribing doctors may be influenced by the psychological effects of ceasing a preventative medication. Physicians may choose not to discuss the stopping of preventative medications, in order to avoid prognostic estimates and emotional distress for the patient \[[@CR11]\]. However, discussion of potential benefits and harms of continuing statin treatment may provide an opportunity for patient centered-decision making \[[@CR23]\].

Another important implication of this study is in the investigation of statin exposure and cancer outcomes. The results from our study suggest that a poor cancer prognosis may influence the probability of remaining exposed to statin treatment. This is known as reverse causation and can lead to biased estimates of associations between post-diagnosis drug exposure and cancer outcomes \[[@CR30]\]. Reverse causation has been highlighted as a threat to the validity of non-randomized studies, and should be dealt with through the inclusion of an exposure lag period, so as to exclude the exposure window prior to death \[[@CR30]\]. Some studies investigating statin exposure and cancer outcomes do not consider the fact that a cancer diagnosis or changes in cancer prognosis may influence the probability of remaining exposed to statins \[[@CR31]--[@CR33]\]. The results from our study show that proximity to death does in fact influence statin exposure, even after matching on predictors of prognosis (age, stage). Our study shows that rates of statin continuation decline prior to death from breast or colorectal cancer, when compared to matched cancer survivors. This occurs in the year prior to death, with rates of statin continuation becoming significantly lower from 3 months prior to a breast or colorectal cancer. This suggests a minimum 3-month lag of statin exposure may be sufficient for reduction in reverse causation bias.

Our study used prospectively collected, high quality-longitudinal prescription information to compare the initiation and continuation of statin treatment in patients who died of breast or colorectal cancer, as compared to those who survived. This allowed us to differentiate between patterns of statin use in breast and colorectal cancer patients, and also in patients who are approaching the end of their lives. A limitation of this study is that prescription refill data is a proxy for medication use, and it may not represent patients who were admitted to hospice care. A study of Irish colorectal cancer patients showed that approximately 13% of end-of-life care occurred in a hospice facility \[[@CR34]\]. In addition, we do not have information on indication for statins or other medications in these patients, or reasons for ceasing treatment. Finally, our study population is defined by eligibility for the GMS scheme, and therefore may over-represent patients who are older and of lower socioeconomic status.

To conclude, a significant proportion of breast and colorectal cancer patients will cease statin treatment as they approach a cancer-specific death. The decline in statin-use occurs up to 1 year prior to death, but becomes statistically significant at least 3 months prior to death. This decline in statin use may be due to different patient or clinical factors, such as a shift in treatment paradigm, or the development of contraindications \[[@CR22]\]. To our knowledge, this is first study to describe longitudinally the statin exposure in a cohort of breast or colorectal cancer patients in the time prior to death, compared to matched cancer-survivors. The results of this study have important implications for (i) the statistical analyses of studies investigating post-diagnostic statin exposure and cancer outcomes; our results suggest that the inclusion of an exposure lag time is vital to account for reverse causation in these studies, and (ii) for the shared decision making process at the end of life, whereby there may be an opportunity to re-evaluate medication burden in this patient group.
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